Hormonal
Obesity in IBD patients is associated with altered pharmacokinetics of biological therapies, leading to faster drug clearance, lower trough concentrations, and potentially reduced treatment efficacy.
If you take biological injections for IBD and are obese, your body might process the drug faster than a lean person's, making it less effective. You should discuss this with your doctor. They might monitor your drug levels more closely or adjust your dose to ensure you get the full benefit of the treatment.
Data from other autoimmune diseases suggest that obesity causes a suboptimal response to therapy, possibly by fast clearance of biologicals causing low trough concentrations... obesity poses technical challenges to colorectal surgery... patients with IBD, obesity, and Clostridium difficile had an increased risk of colectomy...
Why this rating
Based on retrospective studies and mechanistic hypotheses from other autoimmune diseases.
Source
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline
Stephan C. Bischoff et al. · United European Gastroenterology Journal · 2022
DOI 10.1002/ueg2.12280
More from this paper
- In patients with inflammatory bowel disease (IBD) and obesity, weight loss therapy should prioritize selective fat mass reduction while preserving lean body mass (muscle) to avoid worsening sarcopenia and surgical risk.Moderate
- Sarcopenic obesity (high fat mass combined with low muscle mass and function) is a distinct and high-risk phenotype in chronic liver disease (CLD) and IBD, associated with worse prognosis, higher mortality, and increased surgical complications compared to obesity alone or sarcopenia alone.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →